Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm's quarterly revenue was down 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.33) EPS. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA traded down $0.14 during midday trading on Wednesday, hitting $4.98. The stock had a trading volume of 208,801 shares, compared to its average volume of 584,211. The firm has a market cap of $105.53 million, a P/E ratio of -0.91 and a beta of 0.56. Enanta Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $17.80. The company's 50-day simple moving average is $6.56 and its 200 day simple moving average is $10.26.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ENTA. HC Wainwright cut their price objective on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, December 24th. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Enanta Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the business's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 13.64% of the stock is owned by insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.